Daily Respiratory Research Analysis
A phase 3 randomized trial in NEJM shows sacituzumab tirumotecan significantly improves progression-free and overall survival versus chemotherapy in EGFR–TKI–resistant lung cancer. A first-in-human study demonstrates the safety and feasibility of intrarectal perfluorodecalin for enteral ventilation, suggesting a novel adjunct for respiratory support. A 497,185-patient registry analysis links frailty and hypoxemia severity to nonlinear increases in hospital mortality, refining risk stratification
Summary
A phase 3 randomized trial in NEJM shows sacituzumab tirumotecan significantly improves progression-free and overall survival versus chemotherapy in EGFR–TKI–resistant lung cancer. A first-in-human study demonstrates the safety and feasibility of intrarectal perfluorodecalin for enteral ventilation, suggesting a novel adjunct for respiratory support. A 497,185-patient registry analysis links frailty and hypoxemia severity to nonlinear increases in hospital mortality, refining risk stratification in acute hypoxemic respiratory failure.
Research Themes
- Targeted antibody–drug conjugates in EGFR–TKI–resistant lung cancer
- Novel adjunctive oxygenation strategies (enteral ventilation)
- Frailty-integrated risk stratification in acute hypoxemic respiratory failure
Selected Articles
1. Sacituzumab Tirumotecan in EGFR-TKI-Resistant,
In a phase 3 randomized trial (n=376), sacituzumab tirumotecan significantly improved progression-free survival (8.3 vs 4.3 months; HR 0.49) and overall survival (HR 0.60; P=0.001) compared with chemotherapy in EGFR–TKI–resistant lung cancer. Grade ≥3 adverse events were common but manageable, with neutropenia most frequent.
Impact: This RCT demonstrates a survival advantage of a TROP2-targeted ADC over chemotherapy in a major unmet setting, positioning sacituzumab tirumotecan as a potential new standard after EGFR–TKI failure.
Clinical Implications: For EGFR–TKI–resistant lung cancer, sacituzumab tirumotecan may be prioritized over conventional chemotherapy, with close monitoring for neutropenia and other grade ≥3 toxicities.
Key Findings
- Progression-free survival improved to 8.3 months vs 4.3 months (HR 0.49; 95% CI 0.39–0.62).
- Overall survival favored sacituzumab tirumotecan (HR 0.60; 95% CI 0.44–0.82; P=0.001); 18-month OS 65.8% vs 48.0%.
- Grade ≥3 adverse events occurred in 58.0% vs 53.8%; neutropenia was most common (39.9% vs 33.0%).
- Treatment-related serious adverse events were lower with sac-TMT (9.0%) than chemotherapy (17.6%).
Methodological Strengths
- Phase 3 randomized design with hard endpoints (PFS, OS).
- Adequate sample size (n=376) and median follow-up of 18.9 months enabling survival analyses.
Limitations
- Some trial details (eligibility, crossover, stratification factors) are not fully described in the excerpt.
- High rates of grade ≥3 adverse events require careful toxicity management.
Future Directions: Define biomarker-enriched subgroups (e.g., TROP2 expression) and optimize sequencing with other ADCs or targeted agents; evaluate quality-of-life and cost-effectiveness.
BACKGROUND: Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 that has shown significant survival benefits in patients with METHODS: In this phase 3 trial, we enrolled patients with RESULTS: Overall, 376 patients underwent randomization, with 188 assigned to each group. After a median follow-up of 18.9 months, the median progression-free survival was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio for disease progression or death, 0.49; 95% confidence interval [CI], 0.39 to 0.62). Overall survival was significantly longer with sac-TMT than with chemotherapy (hazard ratio for death, 0.60; 95% CI, 0.44 to 0.82; two-sided P = 0.001); 18-month overall survival was 65.8% and 48.0%, respectively. Treatment-related adverse events of grade 3 or higher occurred in 58.0% of patients receiving sac-TMT and in 53.8% of those receiving chemotherapy, with the most common being a decreased neutrophil count (39.9% vs. 33.0%); treatment-related serious adverse events occurred in 9.0% and 17.6%, respectively. CONCLUSIONS: In patients with
2. Safety and tolerability of intrarectal perfluorodecalin for enteral ventilation in a first-in-human trial.
In a phase 1, dose-escalation study (n=27 healthy adults), intrarectal perfluorodecalin was safe and well tolerated with no serious adverse events; mild GI symptoms were transient and dose dependent. Pharmacokinetic modeling and observed signals suggested dose-dependent oxygen transfer, supporting further development of enteral ventilation.
Impact: This is a first-in-human safety study of an entirely new oxygenation route that could complement or bridge respiratory support in hypoxemic failure.
Clinical Implications: While not ready for clinical deployment, enteral perfluorodecalin could evolve into an adjunct for lung rest or transport settings. Future trials in patients and with fully oxygenated perfluorodecalin are warranted.
Key Findings
- No serious adverse events or dose-limiting toxicities across 25–1,500 mL intrarectal perfluorodecalin retained for 60 minutes.
- Mild GI symptoms (bloating, pain) were transient and dose dependent; labs remained normal; systemic exposure was undetectable (<1.0 μg/mL).
- PK modeling predicted dose-dependent oxygenation, aligning with modest SpO2 increases at higher doses.
Methodological Strengths
- Dose-escalation, structured safety monitoring, and laboratory assessments.
- Integration of pharmacokinetic modeling to interpret physiologic oxygen transfer signals.
Limitations
- Healthy volunteers; no patient efficacy data or clinical respiratory endpoints.
- Non-oxygenated perfluorodecalin used; translational effectiveness with oxygenated formulations remains untested.
Future Directions: Evaluate fully oxygenated perfluorodecalin in hypoxemic patients (e.g., ARDS, transport scenarios), define dosing, retention strategies, and interaction with conventional ventilatory support.
BACKGROUND: Enteral ventilation is an emerging approach that provides partial systemic oxygenation independent of pulmonary gas exchange, enabling lung rest. Perfluorodecalin, a clinically approved liquid with high oxygen solubility, is a promising vehicle for enteral oxygen delivery. The primary endpoint of this first-in-human trial was to assess the safety and tolerability of intrarectal perfluorodecalin administration. METHODS: This was a phase 1, single-site, open-label, non-controlled, dose-escalation trial in 27 healthy adult males aged 20-45 years. Participants received a single intrarectal dose of non-oxygenated perfluorodecalin (escalating from 25 to 1,500 mL) retained for 60 min. Safety and tolerability were assessed through monitoring of adverse events, vital signs, clinical laboratory tests, and systemic perfluorodecalin exposure. A pharmacokinetic model using large-animal data was employed to predict potential oxygen transfer. FINDINGS: No serious adverse events or dose-limiting toxicities occurred. Mild gastrointestinal symptoms, such as abdominal bloating and pain, were transient, dose dependent, and resolved without intervention. All clinical laboratory parameters, including liver and renal function markers, remained within normal limits. Perfluorodecalin concentrations were undetectable in blood (<1.0 μg/mL). The pharmacokinetic model predicted a dose-dependent oxygenation effect, consistent with a modest increase in peripheral oxygen saturation observed in the higher-dose group. CONCLUSIONS: This first-in-human study demonstrates that intrarectal administration of non-oxygenated perfluorodecalin is safe, feasible, and well tolerated. These findings establish a critical safety foundation and support the continued development of enteral ventilation with fully oxygenated perfluorodecalin as an adjunctive strategy to support respiratory failure patients. FUNDING: This work was funded by EVA Therapeutics, Inc.
3. The Association Between Frailty, Pa o2 /F io2 Ratio, and Hospital Mortality: A Retrospective Registry-Based Cohort Study.
Across 497,185 ICU admissions, frailty (CFS≥5) was present in 19.6% and was associated with higher AHRF prevalence and mortality. Mortality rose nonlinearly with worsening PaO2/FiO2 and higher frailty, with clear separation across CFS categories after adjustment. Findings support integrating frailty into hypoxemia-based risk stratification.
Impact: This very large, contemporary dataset quantifies how frailty amplifies mortality risk across hypoxemia severities, offering actionable insights for triage, goals-of-care discussions, and ICU resource allocation.
Clinical Implications: Incorporate Clinical Frailty Scale alongside PaO2/FiO2 when prognosticating and planning care in AHRF; consider earlier palliative care involvement and individualized ventilation strategies in frail patients.
Key Findings
- Frailty prevalence was 19.6% (97,317/497,185) and associated with higher AHRF prevalence (58.3% vs 49.0%).
- Overall in-hospital mortality was 7.4%; mortality was markedly higher in frail vs non-frail (16.4% vs 5.2%).
- A nonlinear increase in mortality was observed with worsening PaO2/FiO2 and higher CFS, with clear separation across CFS categories after adjustment.
Methodological Strengths
- Massive multicenter cohort (191 ICUs; n=497,185) with predefined AHRF categories and frailty assessment.
- Robust modeling (restricted cubic splines) and prespecified subgroup analyses.
Limitations
- Retrospective observational design with potential residual confounding and measurement variability.
- Frailty (CFS) and PaO2/FiO2 captured within 24 hours may not reflect dynamic changes over the ICU course.
Future Directions: Prospective studies to test frailty-informed ventilatory strategies and decision-support tools; evaluate interactions with ARDS phenotypes and long-term outcomes.
OBJECTIVES: While research into critically ill patients with acute hypoxemic respiratory failure (AHRF) is growing, how this interacts with frailty is currently unknown. DESIGN: A retrospective multicentric registry-based observational study using the Australia New Zealand Intensive Care Society Adult Patient Database. SETTING AND PATIENTS: All adult (≥ 16 yr) patients admitted to 191 ICUs from January 1, 2017, to March 31, 2023, with an arterial blood gas sample within the first 24 hours were included. We categorized patients as having no AHRF (Pa o2 /F io2 ≥ 300), mild AHRF (Pa o2 /F io2 200-300), moderate AHRF (Pa o2 /F io2 100-200), and severe AHRF (Pa o2 /F io2 < 100). We defined frailty as a Clinical Frailty Scale (CFS) greater than or equal to 5. INTERVENTIONS: None. MAIN OUTCOMES: The primary outcome was in-hospital mortality. MEASUREMENTS AND MAIN RESULTS: We evaluated the association between Pa o2 /F io2 ratio and risk-adjusted mortality using restricted cubic splines with four knots. We conducted predefined subgroup analyses based on age (< 65 vs. ≥ 65 yr), mechanical ventilation status, and patients who survived ICU discharge. We included 497,185 patients; 97,317 had frailty (19.6%). AHRF was more common in patients with frailty compared with those without frailty (58.3% vs. 49.0%). Overall, 7.4% of patients died in hospital (36,791/497,185); a higher proportion were frail (16.4% vs. 5.2%). Mortality rates in patients with frailty with AHRF rose alongside worsening AHRF showing increasing absolute differences in in-hospital mortality as AHRF severity increased. Additionally, within each CFS category, increasing CFS scores also correlated with higher absolute differences in mortality. After adjusting for confounders, there was a nonlinear relationship between frailty, Pa o2 /F io2 , and in-hospital mortality, with a clear separation between each of the CFS categories. CONCLUSIONS: This multicenter, retrospective study that investigated the association between frailty, AHRF, and in-hospital mortality found that AHRF was highly prevalent in patients with frailty. Increasing frailty was associated with higher in-hospital mortality in AHRF and its increasing severity, with a nonlinear relationship.